Full Year Guidance 2010 Reconfirmed

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) today announced its financial results for the six months ending June 30, 2010 according to International Financial Reporting Standards (IFRS). Group revenues increased by 15 % to EUR 43.5 million (H1 2009: EUR 37.9 million) and operating profit increased by 26 % to EUR 8.3 million (H1 2009: EUR 6.6 million). Net profit amounted to EUR 5.9 million (H1 2009: EUR 5.0 million), a gain of 18 % over the same period of the previous year. As planned, MorphoSys further increased its investment in proprietary research and development to EUR 11.1 million (H1 2009: EUR 8.5 million). MorphoSys's cash position on June 30, 2010 was EUR 152.1 million (December 31, 2009: EUR 135.1 million). The cash position at balance sheet date still includes the outstanding up-front payment of approx. EUR 10.5 million, which was paid to Xencor in early July. The Company re-confirmed its full year guidance for 2010.

Highlights of the Second Quarter of 2010

• MorphoSys and US-based biopharmaceutical company Xencor signed a worldwide exclusive license and collaboration agreement for an anti-CD19 antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574 (now MOR208), a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies.
• MorphoSys's drug pipeline now comprises 72 therapeutic antibody programs in total, of which eleven are currently in clinical development, 26 are in preclinical development and 35 are in the discovery phase. Eight of these are MorphoSys's proprietary programs, including a joint pre-development program with Novartis. MOR103, currently in a Phase 1b/2a clinical study in rheumatoid arthritis patients, is the most advanced proprietary program.
• In May 2010, a first HuCAL antibody, developed by Novartis, achieved clinical proof of concept in an undisclosed indication.
• During the second quarter of 2010, MorphoSys received two phase 1 milestones, namely from Centocor and Novartis, for two partnered antibodies commencing clinical development.
• In June 2010, MorphoSys received a grant from the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 1 million supports MorphoSys in accelerating the development of its HuCAL-based cancer program MOR202 for the treatment of multiple myeloma. The program is part of Munich's biotechnology initiative 'm4 - Personalized Medicine and Targeted Therapies - A New Dimension in Drug Development in the Munich Region'.
• MorphoSys's annual shareholder meeting, which took place in Munich on Friday, May 21, 2010, approved all management proposals put to vote at the meeting, including an authorization to repurchase shares.

'MorphoSys has become a credible development organization with a unique financial profile over the course of the last 18 months,' commented Dave Lemus, Chief Financial Officer of MorphoSys AG. 'Our goal has been, and remains, to build a sustainable portfolio of antibody drug candidates, while maintaining our financial discipline.'

'Our therapeutic antibody pipeline continues to expand and mature. By in-licensing a promising, highly innovative Phase 1 antibody from Xencor, we took a significant step in the execution of our plan to build a strong portfolio of proprietary therapeutic antibodies to complement those being developed by our partners,' commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. 'Our exceptionally strong cash-flow is enabling us to drive a substantial proprietary research and development effort, which is a very important value driver for the Company. We're on track to achieving the goals we set ourselves at the beginning of the year, in both the therapeutic and AbD Serotec business segments.'

Financial Review for the First Six Months of 2010 (IFRS)

Group revenues for the first six months of 2010 amounted to EUR 43.5 million (H1 2009: EUR 37.9 million), an increase of 15 % over the prior year. Segment revenues arising from the Partnered Discovery segment accounted for EUR 32.8 million of the total (H1 2009: EUR 28.1 million) and included success-based payments in the amount of EUR 3.6 million (H1 2009: EUR 5.4 million). The Proprietary Development segment, comprising the Company's own and joint drug development activities contributed EUR 0.6 million to total revenues (H1 2009: EUR 0.5 million). These revenues arise from Novartis's funding of a joint pre-development program. Revenues in the Research and Diagnostics segment AbD Serotec increased by 9 % to EUR 10.6 million (H1 2009: EUR 9.7 million). Measured at constant foreign exchange rates as of H1 2009, segment revenues in the Partnered Discovery and Proprietary Development segments would have remained unchanged and revenues in the AbD Serotec segment would have amounted to EUR 10.4 million.

Total operating expenses for the first six months of 2010 amounted to EUR 35.2 million (H1 2009: EUR 31.3 million), representing an increase of 12 % over the prior year, which was mainly the result of a higher level of investment in proprietary drug development, as planned. Cost of goods sold (COGS) increased in comparison to the first six months of 2009 by 15 % to EUR 3.8 million. Research and development expenses increased by 14 % to EUR 20.5 million (H1 2009: EUR 18.0 million). These R&D expenses comprised costs for proprietary product and technology development in the amount of EUR 11.1 million (H1 2009: EUR 8.5 million) as well as costs incurred on behalf of partners. Sales, general and administrative expenses increased by 9 % to EUR 10.9 million (H1 2009: EUR 10.0 million). Non-cash charges related to stock-based compensation are embedded in COGS, S, G&A and R&D expenses and amounted to EUR 1.0 million (H1 2009: EUR 0.8 million). Total operating profit amounted to EUR 8.3 million (H1 2009: EUR 6.6 million).

The segment income for the Partnered Discovery segment amounted to EUR 22.2 million (H1 2009: EUR 18.0 million), while the Proprietary Development segment showed a segment loss of EUR 10.5 million (H1 2009: segment loss of EUR 8.0 million). In the AbD Serotec segment, operating profit decreased to EUR 0.9 million (H1 2009: EUR 1.1 million) and would have amounted to € 0.9 million under the assumption of constant foreign exchange rates at the average rate of H1 2009. Unallocated corporate costs in the first six months of 2010 amounted to EUR 4.3 million (H1 2009: EUR 4.4 million).

For the first six months of 2010, non-operating income amounted to EUR 0.4 million (H1 2009: non-operating income of EUR 1.1 million). Profit before taxes amounted to EUR 8.7 million (H1 2009: EUR 7.7 million).

For the first six months of 2010, the Company reported income tax expenses in the amount of EUR 2.9 million (H1 2009: EUR 2.7 million).

Net profit for the first six months of 2010 amounted to EUR 5.9 million (H1 2009: EUR 5.0 million). The resulting diluted earnings per share for the first six months of 2010 amounted to EUR 0.26 (H1 2009: Diluted earnings per share of EUR 0.22).

On June 30, 2010, the Company had EUR 152.1 million in cash, cash equivalents, and marketable securities, compared to EUR 135.1 million as of December 31, 2009. Net cash inflow from operations in the first six months of 2010 amounted to EUR 28.5 million (H1 2009: cash inflow of EUR 6.6 million). The number of issued shares at June 30, 2010 was 22,677,078, compared to 22,660,557 shares at December 31, 2009.

Financial Review for the Second Quarter of 2010 (IFRS)

In the second quarter of 2010, revenues increased by 22 % to EUR 22.9 million, compared to EUR 18.7 million in the same quarter of 2009. Total operating expenses amounted to EUR 19.3 million, compared to EUR 16.4 million in the same period of 2009. The resulting profit from operations for the second quarter of 2010 amounted to EUR 3.6 million, compared to EUR 2.4 million in the same period of 2009. A net profit of EUR 2.7 million was achieved in the second quarter of 2010, compared to EUR 1.5 million during the same period in 2009.